Dr. Penelope Bradbury
Key Inclusion Criteria:
- Participant must be ≥ 18 years at the time of screening
- Histologically proven diagnosis of pleural mesothelioma with known histology
(epithelioid vs. non-epithelioid)
- Advanced unresectable disease that cannot be treated with curative surgery (with or
without chemotherapy)
- WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS>1)
over the previous 2 weeks prior to day of first dosing
- Has measurable disease per modified RECIST1.1
- Has adequate bone marrow reserve and organ function at baseline
Key Exclusion Criteria:
- As judged by the investigator, any condition that would interfere with evaluation of
the investigational product or interpretation of participant safety or study
results.
- Active or prior documented autoimmune or inflammatory disorders
- History of another primary malignancy with exceptions.
- Uncontrolled intercurrent illness
- Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus
(HIV) infection that is not well controlled
- Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal
therapy for cancer treatment
- Untreated or progressive CNS metastatic disease
